By Gary M. White, MD
Note: This is a summary only. Please consult the latest information when prescribing.
- Recombinanat IgG1 monoclonocal antibody
- High affinity for TNF-alpha
Adalimumab and Psoriasis
- Pasi 75 of 77% at week 12
- Efficacious in psoriatic arthritis and inflammatory bowel disease.
- There can be loss of efficacy related to anti-drug antibodies
- Moderate to severe chronic plaque psoriasis in adults.
- Moderate to severe rheumatoid arthritis in adults.
- Moderate to severe polyarticular juvenile idiopathic arthritis in children 4 years of age and older.
- Psoriatic arthritis in adults.
- Ankylosing spondylitis in adults.
- Moderate to severe Crohn's disease in adults and children 6 years and older.
- Moderate to severe ulcerative colitis in adults.
Black Box Warnings
SERIOUS INFECTION Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.
MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including HUMIRA.
Dose for Psoriasis
80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.
Limited data from published literature indicate that adalimumab is present in low levels in human milk and is not likely to be absorbed by a breastfed infant. However, no data is available on the absorption of adalimumab from breast milk in newborn or preterm infants. Caution should be exercised when HUMIRA is administered to a nursing woman.
It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.